Motixafortide Acetate

Summary

Motixafortide Acetate (CHEMBL5095449) is an approved protein; indicated across 3 conditions including plasma cell myeloma and neoplasm.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• Indications: 3 conditions

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5095449
Name	Motixafortide Acetate
Type	Protein
Max phase	4

Also known as: Aphexda, BL-8040 acetate, Motixafortide acetate, TF-14016 ACETATE, MOTIXAFORTIDE ACETATE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
plasma cell myeloma	4	MONDO:0009693	EFO:0001378

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
neoplasm	1	MONDO:0005070	EFO:0000616

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).